Abstract
Bayer and Onyx are developing BAY-43-9006, an oral cytostatic Raf kinase inhibitor for the potential treatment of colorectal and breast cancers, hepatocellular carcinoma and non-small-cell lung cancer, in addition to acute myelogenous leukemia, myelodysplastic syndrome and other cancers. A US IND was filed in May 2000 and by February 2003 BAY-43-9006 was in phase II trials, with phase III trials expected to begin later in 2003.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Animals
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / metabolism
-
Antineoplastic Agents / therapeutic use*
-
Benzenesulfonates / chemistry
-
Benzenesulfonates / metabolism
-
Benzenesulfonates / therapeutic use*
-
Clinical Trials as Topic / statistics & numerical data
-
Drugs, Investigational* / chemistry
-
Drugs, Investigational* / metabolism
-
Drugs, Investigational* / therapeutic use
-
Humans
-
Neoplasms / drug therapy
-
Neoplasms / metabolism
-
Niacinamide / analogs & derivatives
-
Phenylurea Compounds
-
Pyridines / chemistry
-
Pyridines / metabolism
-
Pyridines / therapeutic use*
-
Sorafenib
-
Technology, Pharmaceutical / methods*
Substances
-
Antineoplastic Agents
-
Benzenesulfonates
-
Drugs, Investigational
-
Phenylurea Compounds
-
Pyridines
-
Niacinamide
-
Sorafenib